Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
116.60
+0.05 (+0.04%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
June 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)
June 13, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023
June 12, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck & Company Inc. (NYSE: MRK) Climbs to New 52-Week High
April 17, 2023
Via
Investor Brand Network
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
June 08, 2023
From
Merck & Co., Inc.
Via
Business Wire
U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
June 06, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Merck & Co., Inc.
Via
Business Wire
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
June 05, 2023
Via
ACCESSWIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
June 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
June 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
June 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
May 30, 2023
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin
Via
MarketBeat
Topics
Death
Exposures
Death
Product Safety
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Third-Quarter 2023 Dividend
May 23, 2023
From
Merck & Co., Inc.
Via
Business Wire
Doximity is an Overlooked Medical Ecosystem AI Play
May 23, 2023
Doximity Inc. (NASDAQ: DOCS) is a digital professional social network platform for medical practitioners. It’s a medical community networking platform like
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
May 18, 2023
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
May 15, 2023
From
Merck & Co., Inc.
Via
Business Wire
3 Underperforming Nasdaq 100 Stocks Worth a Closer Look
May 04, 2023
Given the volatility and growth potential associated with the Nasdaq’s elite, investors may want to keep these recent underperformers on the watch list.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Merck to Participate in Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
May 02, 2023
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
Via
MarketBeat
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
May 02, 2023
Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
May 01, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
April 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces First-Quarter 2023 Financial Results
April 27, 2023
From
Merck & Co., Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
April 25, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
April 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry
April 18, 2023
EQNX::TICKER_START (NASDAQ:CELH),(NASDAQ:OMER),(NYSE:MRK),(NASDAQ:RXDX) EQNX::TICKER_END
Via
FinancialNewsMedia
Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right
April 18, 2023
When a biotech company delivers chart-busting news, more often follows. In a space that can be like throwing darts, Wall Street has bullseyes on Vaxcyte, Inc.
Via
MarketBeat
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
April 16, 2023
Via
ACCESSWIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
April 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.